Media Welcome to Guerbet Media section for journalists. The press releases are intended for their professional use. Find our latest press releases and our media resources. Media… Homepage Media Our Latest Press Releases Intrasense and Guerbet announce PMDA certification in Japan for DUOnco™ Pancreas, an AI software designed to support the reading of pancreatic areas on contrast-enhanced CT Read the article Changes to the Composition of Guerbet’s Board of Directors Read the article Guerbet announces an important milestone achievement in the “Vascular Embolization” indication for Lipiodol® Ultra Fluid (Iodinated ethyl esters of fatty acids of poppy seed oil) Read the article - Any - 2026 2025 2024 2023 2022 2021 2020 2019 2018 ApplyClear Filters First-half 2023 revenue Read the article Half-year results 2023 Read the article 2022 annual results Read the article Q1 2023 Revenue Read the article The CHMP issues an opinion in favour of granting an EU marketing authorisation for Elucirem™ (Gadopiclenol) with the indication of use for magnetic resonance imaging with contrast enhancement in adults and children aged 2 years and over Read the article Revenue at 30 September 2023 Read the article Guerbet announces marketing authorisation approval of Elucirem™ (Gadopiclenol) in the European Union Read the article Guerbet announces U.S. Food and Drug Administration (FDA) approval of Elucirem™ (Gadopiclenol) Read the article Guerbet announces a change in governance for its Artificial Intelligence projects Read the article ‹ 1 2 3 4 Current page5 6 7 8 9 ›
Intrasense and Guerbet announce PMDA certification in Japan for DUOnco™ Pancreas, an AI software designed to support the reading of pancreatic areas on contrast-enhanced CT Read the article
Guerbet announces an important milestone achievement in the “Vascular Embolization” indication for Lipiodol® Ultra Fluid (Iodinated ethyl esters of fatty acids of poppy seed oil) Read the article
The CHMP issues an opinion in favour of granting an EU marketing authorisation for Elucirem™ (Gadopiclenol) with the indication of use for magnetic resonance imaging with contrast enhancement in adults and children aged 2 years and over Read the article
Guerbet announces marketing authorisation approval of Elucirem™ (Gadopiclenol) in the European Union Read the article
Guerbet announces U.S. Food and Drug Administration (FDA) approval of Elucirem™ (Gadopiclenol) Read the article
